Tonix Pharmaceuticals Holding Corp.TNXP
Price (close)
$9.70
Market cap
$166.4M
P/E
—
Revenue (TTM)
$29.1M
Net income
-$159.7M
Dividend yield
—
1-year total return
-59.6%
Net margin
-548.6%
Revenue growth
196.0%
Debt / equity
—
What Tonix Pharmaceuticals Holding Corp. does.
Annual Report on Form 10-K (including the section regarding Management’s Discussion and Analysis of Financial Condition and
Results of Operations) contains forward-looking statements regarding our business, financial condition, results of operations and
prospects. All statements contained in this Annual Report other than statements of historical fact, including, but not limited to,
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $7.8M | $10.1M | $13.1M |
| Net income | -$50.5M | -$92.3M | -$110.2M | -$116.7M | -$130.0M | -$124.0M |
| Free cash flow | -$57.1M | -$110.9M | -$146.2M | -$109.9M | -$61.0M | -$103.2M |
More on TNXP.
- Tonix Pharmaceuticals Holding Corp. summary
- Tonix Pharmaceuticals Holding Corp. financial statements
- Tonix Pharmaceuticals Holding Corp. key metrics
- Tonix Pharmaceuticals Holding Corp. health scores and style box
- Tonix Pharmaceuticals Holding Corp. earnings
- Tonix Pharmaceuticals Holding Corp. dividends
- Tonix Pharmaceuticals Holding Corp. valuation
- Tonix Pharmaceuticals Holding Corp. ownership and insiders
- Tonix Pharmaceuticals Holding Corp. peers
Figures from Tonix Pharmaceuticals Holding Corp.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.